Gilead Sciences (GILD) Income towards Parent Company (2009 - 2026)
Gilead Sciences posted quarterly Income towards Parent Company of $2.0 billion for Q1 2026, up 53.69% year-on-year from $1.3 billion in Q1 2025, and down 20.06% on a QoQ basis from $2.5 billion in Q4 2025.
Gilead Sciences (GILD) has 18 years of Income towards Parent Company data on file, last reported at $2.0 billion in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company rose 53.69% year-over-year to $2.0 billion; the trailing twelve-month figure through Mar 2026 stood at $9.6 billion (up 60.3% YoY), and the FY2025 full-year result was $8.5 billion, up 1676.62% from the prior year.
- Income towards Parent Company for Q1 2026 stood at $2.0 billion, down from $2.5 billion in the prior quarter.
- Across five years, Income towards Parent Company topped out at $3.1 billion in Q3 2025 and bottomed at -$4.2 billion in Q1 2024.
- The 5-year median for Income towards Parent Company is $1.6 billion (2024), against an average of $1.3 billion.
- The widest annual swing landed in 2023, when Income towards Parent Company jumped 8100.0%; it then plunged 523.88% in 2024.
- A 5-year view of Income towards Parent Company shows it stood at $1.6 billion in 2022, then declined by 13.29% to $1.4 billion in 2023, then climbed by 25.85% to $1.8 billion in 2024, then jumped by 41.86% to $2.5 billion in 2025, then declined by 20.06% to $2.0 billion in 2026.
- The last three Income towards Parent Company figures came in at $2.0 billion (Q1 2026), $2.5 billion (Q4 2025), and $3.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.02 Bn |
| Dec 31, 2025 | 2.53 Bn |
| Sep 30, 2025 | 3.05 Bn |
| Jun 30, 2025 | 1.96 Bn |
| Mar 31, 2025 | 1.32 Bn |
| Dec 31, 2024 | 1.78 Bn |
| Sep 30, 2024 | 1.25 Bn |
| Jun 30, 2024 | 1.62 Bn |
| Mar 31, 2024 | -4.17 Bn |
| Dec 31, 2023 | 1.42 Bn |
| Sep 30, 2023 | 2.17 Bn |
| Jun 30, 2023 | 1.04 Bn |
| Mar 31, 2023 | 984.00 Mn |
| Dec 31, 2022 | 1.63 Bn |
| Sep 30, 2022 | 1.79 Bn |
| Jun 30, 2022 | 1.14 Bn |
| Mar 31, 2022 | 12.00 Mn |
| Dec 31, 2021 | 376.00 Mn |
| Sep 30, 2021 | 2.59 Bn |
| Jun 30, 2021 | 1.51 Bn |
| Mar 31, 2021 | 1.71 Bn |
| Dec 31, 2020 | 1.53 Bn |
| Sep 30, 2020 | 327.00 Mn |
| Jun 30, 2020 | -3.46 Bn |
| Mar 31, 2020 | 1.43 Bn |
| Dec 31, 2019 | 576.00 Mn |
| Sep 30, 2019 | -1.30 Bn |
| Jun 30, 2019 | 1.74 Bn |
| Mar 31, 2019 | 1.83 Bn |
| Dec 31, 2018 | 281.00 Mn |
| Sep 30, 2018 | 1.95 Bn |
| Jun 30, 2018 | 1.76 Bn |
| Mar 31, 2018 | 1.48 Bn |
| Dec 31, 2017 | -3.73 Bn |
| Sep 30, 2017 | 2.30 Bn |
| Jun 30, 2017 | 2.66 Bn |
| Mar 31, 2017 | 2.22 Bn |
| Dec 31, 2016 | 2.62 Bn |
| Sep 30, 2016 | 2.83 Bn |
| Jun 30, 2016 | 2.92 Bn |
| Mar 31, 2016 | 3.57 Bn |
| Dec 31, 2015 | 4.11 Bn |
| Sep 30, 2015 | 4.06 Bn |
| Jun 30, 2015 | 4.15 Bn |
| Mar 31, 2015 | 3.92 Bn |
| Dec 31, 2014 | 3.07 Bn |
| Sep 30, 2014 | 2.43 Bn |
| Jun 30, 2014 | 3.31 Bn |
| Mar 31, 2014 | 1.91 Bn |
| Dec 31, 2013 | 411.46 Mn |
| Sep 30, 2013 | 476.35 Mn |
| Jun 30, 2013 | 516.23 Mn |
| Mar 31, 2013 | 477.47 Mn |
| Dec 31, 2012 | 518.23 Mn |
| Sep 30, 2012 | 524.52 Mn |
| Jun 30, 2012 | 624.81 Mn |
| Mar 31, 2012 | 387.06 Mn |
| Dec 31, 2011 | 533.27 Mn |
| Sep 30, 2011 | 737.54 Mn |
| Jun 30, 2011 | 742.46 Mn |
| Mar 31, 2011 | 647.30 Mn |
| Dec 31, 2010 | 626.37 Mn |
| Sep 30, 2010 | 702.16 Mn |
| Jun 30, 2010 | 709.13 Mn |
| Mar 31, 2010 | 852.09 Mn |
| Dec 31, 2009 | 1.51 Bn |
| Sep 30, 2009 | 670.48 Mn |
| Jun 30, 2009 | 569.15 Mn |
| Mar 31, 2009 | 586.58 Mn |